Top

Published in:

Open Access 01-07-2021 | Diseases of the neuromuscular synapses and muscles | Inflammatory Muscle Disease (L Diederichsen and H Chinoy, Section Editor)

Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management

Authors: Anett Vincze, János Gaál, Zoltán Griger

Published in: Current Rheumatology Reports | Issue 7/2021

Abstract

Purpose of Review

This article provides an update on the most recent advances in epidemiology, pathogenesis, diagnostic procedures, and therapeutic approaches for myositis-associated bone diseases, such as osteoporosis and bone fractures.

Recent Findings

In the recent years, several studies showed that osteoporosis and consequent fractures are a common and frequently underestimated complication in patients with idiopathic inflammatory myopathies (IIM). In younger patients, asymptomatic fractures might present in the early phase of the disease which could increase the risk of development of further fractures. High-risk patients could be selected with early application of combined diagnostic procedures, such as fracture risk scores with steroid dose adjustments and imaging.

Summary

Recent advances might help clinicians from different fields of medicine in the early recognition and management of myositis-associated osteoporosis, which will potentially improve the quality of life of patients with IIM.

Oldroyd A, Chinoy H. Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2018;30(6):606–13. https://doi.org/10.1097/BOR.0000000000000549.CrossRefPubMedPubMedCentral

Topp R, Ditmyer M, King K, Doherty K, Hornyak J 3rd. The effect of bed rest and potential of prehabilitation on patients in the intensive care unit. AACN Clin Issues. 2002;13(2):263–76. https://doi.org/10.1097/00044067-200205000-00011.CrossRefPubMed

Bloomfield SA. Changes in musculoskeletal structure and function with prolonged bed rest. Med Sci Sports Exerc. 1997;29(2):197–206. https://doi.org/10.1097/00005768-199702000-00006.CrossRefPubMed

Parry SM, Puthucheary ZA. The impact of extended bed rest on the musculoskeletal system in the critical care environment. Extrem Physiol Med. 2015;4:16. Published 2015 Oct 9. https://doi.org/10.1186/s13728-015-0036-7.CrossRefPubMedPubMedCentral

Tripoli A, Marasco E, Cometi L, de Stefano L, Marcucci E, Furini F, et al. One year in review 2019: idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2020;38(1):1–10.PubMed

Ishikawa Y, Iwata S, Hanami K, et al. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 2018;20(1):240. Published 2018 Oct 26. https://doi.org/10.1186/s13075-018-1737-2.CrossRefPubMedPubMedCentral

Zou YQ, Jin WD, Li YS. Roles of macrophage migration inhibitory factor in polymyositis: inflammation and regeneration. J Int Med Res. 2018;46(2):732–8. https://doi.org/10.1177/0300060517726194.CrossRefPubMed

Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012;8(11):684–9. https://doi.org/10.1038/nrrheum.2012.167.CrossRefPubMed

• Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16. https://doi.org/10.1007/s12020-018-1588-2This work contains the most important knowledge about the pathophysiology of GIOP.CrossRefPubMedPubMedCentral

10.

Harvey NC, McCloskey EV, Mitchell PJ, et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507–29. https://doi.org/10.1007/s00198-016-3894-y.CrossRefPubMedPubMedCentral

11.

Hsu E, Nanes M. Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2017;24(6):411–7. https://doi.org/10.1097/MED.0000000000000368.CrossRefPubMedPubMedCentral

12.

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709–18. https://doi.org/10.1007/s00198-015-3455-9.CrossRefPubMed

13.

Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology. 2006;147(7):3613–22. https://doi.org/10.1210/en.2005-0717.CrossRefPubMed

14.

Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140(10):4382–9. https://doi.org/10.1210/endo.140.10.7034.CrossRefPubMed

15.

Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 2019;14:41–50. Published 2019 Aug 23. https://doi.org/10.2147/CE.S172820.CrossRefPubMedPubMedCentral

16.

Mo H, Zhang N, Li H, Li F, Pu R. Beneficial effects of Cuscuta chinensis extract on glucocorticoid-induced osteoporosis through modulation of RANKL/OPG signals. Braz J Med Biol Res. 2019;52(12):e8754. Published 2019 Dec 5. https://doi.org/10.1590/1414-431X20198754.CrossRefPubMedPubMedCentral

17.

Yu SF, Chen JF, Chen YC, Lai HM, Ko CH, Chiu WC, et al. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: a nationwide osteoporosis survey. Medicine (Baltimore). 2017;96(5):e5959. https://doi.org/10.1097/MD.0000000000005959.CrossRefPubMedCentral

18.

Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17(1):105–8. https://doi.org/10.1007/s00198-005-1923-3.CrossRefPubMed

19.

• Vincze A, Bodoki L, Szabó K, et al. The risk of fracture and prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional study from a single Hungarian center. BMC Musculoskelet Disord. 2020;21(1):426. Published 2020 Jul 2. https://doi.org/10.1186/s12891-020-03448-2This study compare fracture risk, BMD and the prevalence of vertebral fractures in patients with IIM and RA and assess the effect of fractures on the quality of life and functional capacity.

20.

So H, Yip ML, Wong AK. Prevalence and associated factors of reduced bone mineral density in patients with idiopathic inflammatory myopathies. Int J Rheum Dis. 2016;19(5):521–8. https://doi.org/10.1111/1756-185X.12405.CrossRefPubMed

21.

• Gupta L, Lawrence A, Edavalath S, Misra R. Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis. Int J Rheum Dis. 2018;21(3):725–31. https://doi.org/10.1111/1756-185X.13257This is the first study, which aimed to assess the prevalence of asymptomatic vertebral fractures in adult patients with IIM.CrossRefPubMed

22.

Lee CW, Muo CH, Liang JA, Sung FC, Hsu CY, Kao CH. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score. Endocrine. 2016;52(1):86–92. https://doi.org/10.1007/s12020-015-0756-x.CrossRefPubMed

23.

de Andrade DC, de Magalhães Souza SC, de Carvalho JF, et al. High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. Rheumatol Int. 2012;32(6):1549–53. https://doi.org/10.1007/s00296-011-1821-2.CrossRefPubMed

24.

Ng KP, Ramos F, Sultan SM, Isenberg DA. Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol. 2009;28(8):947–53. https://doi.org/10.1007/s10067-009-1181-4.CrossRefPubMed

25.

Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford). 2005;44(1):83–8. https://doi.org/10.1093/rheumatology/keh404.CrossRef

26.

•• Ganguly S, Lawrence A, Gupta L. Prevalent vertebral fractures incur high risk of future fractures in inflammatory myositis [published online ahead of print, 2020 Sep 6]. Clin Rheumatol. 2020. https://doi.org/10.1007/s10067-020-05365-0This is the only longitudinal study following a myositis cohort in the aspect of vertebral fractures. It concludes that IIM patients with a prior vertebral fracture incurred a five times risk of subsequent vertebral fracture irrespective of disease activity and glucocorticoids.

27.

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published correction appears in Osteoporos Int. 2020 Jan;31(1):209] [published correction appears in Osteoporos Int. 2020 Apr;31(4):801]. Osteoporos Int. 2019;30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5.CrossRefPubMed

28.

Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. https://doi.org/10.1007/s11657-017-0324-5.CrossRefPubMedPubMedCentral

29.

Matsuno H. Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R D. 2016;16(4):347–53. https://doi.org/10.1007/s40268-016-0146-8.CrossRefPubMedPubMedCentral

30.

Watts NB. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int. 2004;15(11):847–54. https://doi.org/10.1007/s00198-004-1681-7.CrossRefPubMed

31.

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis [published correction appears in Osteoporos Int. 2015 Jul;26(7):2045-7]. Osteoporos Int. 2014;25(10):2359–81. https://doi.org/10.1007/s00198-014-2794-2.CrossRefPubMedPubMedCentral

32.

Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97. https://doi.org/10.1007/s00198-007-0543-5.CrossRefPubMedPubMedCentral

33.

Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–16. https://doi.org/10.1007/s00198-010-1524-7.CrossRefPubMed

34.

Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229. Published 2009 Nov 19. https://doi.org/10.1136/bmj.b4229.CrossRefPubMedPubMedCentral

35.

Kanis JA, Harvey NC, Johansson H, Odén A, McCloskey EV, Leslie WD. Overview of fracture prediction tools. J Clin Densitom. 2017;20(3):444–50. https://doi.org/10.1016/j.jocd.2017.06.013.CrossRefPubMedPubMedCentral

36.

Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431–44. https://doi.org/10.1007/s00198-008-0588-0.CrossRefPubMed

37.

Genant HK, Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int. 2003;14(Suppl 3):S43–55. https://doi.org/10.1007/s00198-002-1348-1.CrossRefPubMed

38.

Grados F, Fechtenbaum J, Flipon E, Kolta S, Roux C, Fardellone P. Radiographic methods for evaluating osteoporotic vertebral fractures. Joint Bone Spine. 2009;76(3):241–7. https://doi.org/10.1016/j.jbspin.2008.07.017.CrossRefPubMed

39.

• Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14(1):85–102. https://doi.org/10.1007/s11739-018-1874-2This work widely summarize the available methods to diagnose osteoporosis and the pharmacological and non pharmacological treatment options.CrossRefPubMed

40.

Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908–23. https://doi.org/10.1016/S2213-8587(17)30184-5.CrossRefPubMed

41.

Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J, et al. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320(9):554–8. https://doi.org/10.1056/NEJM198903023200903.CrossRefPubMed

42.

Nikander R, Sievänen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P. Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life. BMC Med. 2010;8:47. Published 2010 Jul 21. https://doi.org/10.1186/1741-7015-8-47.CrossRefPubMedPubMedCentral

43.

Iuliano-Burns S, Stone J, Hopper JL, Seeman E. Diet and exercise during growth have site-specific skeletal effects: a co-twin control study. Osteoporos Int. 2005;16(10):1225–32. https://doi.org/10.1007/s00198-004-1830-z.CrossRefPubMed

44.

Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations [published correction appears in Osteoporos Int. 2016 Apr;27(4):1387]. Osteoporos Int. 2016;27(4):1281–386. https://doi.org/10.1007/s00198-015-3440-3.CrossRefPubMedPubMedCentral

45.

Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387–94. https://doi.org/10.1001/jama.297.4.387.CrossRefPubMed

46.

Baum JI, Kim IY, Wolfe RR. Protein consumption and the elderly: what is the optimal level of intake? Nutrients. 2016;8(6):359. Published 2016 Jun 8. https://doi.org/10.3390/nu8060359.CrossRefPubMedCentral

47.

Coronado-Zarco R, Olascoaga-Gómez de León A, García-Lara A, Quinzaños-Fresnedo J, Nava-Bringas TI, Macías-Hernández SI. Nonpharmacological interventions for osteoporosis treatment: systematic review of clinical practice guidelines. Osteoporos Sarcopenia. 2019;5(3):69–77. https://doi.org/10.1016/j.afos.2019.09.005.CrossRefPubMedPubMedCentral

48.

Stenhagen M, Nordell E, Elmståhl S. Falls in elderly people: a multifactorial analysis of risk markers using data from the Swedish general population study 'Good ageing in Skåne'. Aging Clin Exp Res. 2013;25(1):59–67. https://doi.org/10.1007/s40520-013-0015-z.CrossRefPubMed

49.

Hopewell S, Adedire O, Copsey BJ, et al. Multifactorial and multiple component interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2018;7(7):CD012221. Published 2018 Jul 23. https://doi.org/10.1002/14651858.CD012221.pub2.CrossRefPubMed

50.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82. https://doi.org/10.1001/jama.280.24.2077.CrossRefPubMed

51.

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group [published correction appears in J Clin Endocrinol Metab 2001 Feb;86(2):938]. J Clin Endocrinol Metab. 2000;85(11):4118–24. https://doi.org/10.1210/jcem.85.11.6953.CrossRefPubMed

52.

Harris ST, Watts NB, Genant HK, McKeever C, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–52. https://doi.org/10.1001/jama.282.14.1344.CrossRefPubMed

53.

Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy [published correction appears in Osteoporos Int. 2013 Aug;24(8):2375-6]. Osteoporos Int. 2013;24(8):2345–52. https://doi.org/10.1007/s00198-013-2332-7.CrossRefPubMed

54.

Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–9. https://doi.org/10.1359/JBMR.040325.CrossRefPubMed

55.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. https://doi.org/10.1056/NEJMoa067312.CrossRefPubMed

56.

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://doi.org/10.1001/jama.288.3.321.CrossRefPubMed

57.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [published correction appears in JAMA 1999 Dec 8;282(22):2124]. JAMA. 1999;282(7):637–45. https://doi.org/10.1001/jama.282.7.637.CrossRefPubMed

58.

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [published correction appears in N Engl J Med. 2009 Nov 5;361(19):1914]. N Engl J Med. 2009;361(8):756–65. https://doi.org/10.1056/NEJMoa0809493.CrossRefPubMed

59.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. https://doi.org/10.1056/NEJM200105103441904.CrossRefPubMed

60.

Davis S, Simpson E, Hamilton J, James MMS, Rawdin A, Wong R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess. 2020;24(29):1–314. https://doi.org/10.3310/hta24290.CrossRefPubMedPubMedCentral

61.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [published correction appears in JAMA. 2017 Jan 24;317(4):442]. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.CrossRefPubMed

62.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.CrossRefPubMed

63.

McCloskey EV, Johansson H, Oden A, Kanis JA. From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep. 2009;7(3):77–83. https://doi.org/10.1007/s11914-009-0013-4.CrossRefPubMed

64.

• Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019;104(3):235–8. https://doi.org/10.1007/s00223-018-00512-xBriefly summarize the main recommendations for the diagnosis and management of osteoporosis in postmenopausal women.CrossRefPubMedPubMedCentral

65.

Cosman F. Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture [published online ahead of print, 2020 Mar 11]. Endocr Pract. 2020. https://doi.org/10.4158/EP-2019-0596.

66.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis [published correction appears in Arthritis Rheumatol. 2017 Nov;69(11):2246]. Arthritis Rheumatol. 2017;69(8):1521–37. https://doi.org/10.1002/art.40137.CrossRefPubMed

Title: Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management
Authors: Anett Vincze
János Gaál
Zoltán Griger
Publication date: 01-07-2021
Publisher: Springer US
Keywords: Diseases of the neuromuscular synapses and muscles
Glucocorticoid
Osteoporosis
Osteoporosis
Myopathy
Published in: Current Rheumatology Reports / Issue 7/2021
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-021-01016-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2021

Correction to: Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Updates on the Immunopathology in Idiopathic Inflammatory Myopathies

Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia

Dietary and Lifestyle-Centered Approach in Gout Care and Prevention

Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens

The Nasal Microbiome in ANCA-Associated Vasculitis: Picking the Nose for Clues on Disease Pathogenesis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials